Structure-Based Receptor MIMICS Targeted Against Bacterial Superantigen Toxins

The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome.

Available for  

  • thumbnail of
  • Feynman Center
  • (505) 665-9090
  • Email

Structure-Based Receptor MIMICS Targeted Against Bacterial Superantigen Toxins

The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class II receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen "receptor mimetics" or "chimeras" are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.

U.S. Patent No.: 7,576,183 (DOE S-99,945)

Patent Application Filing Date: December 24, 2003

Patent Issue Date: August 18, 2009

Licensing Status:

Available for Express Licensing(?). View terms and a sample license agreement.

For more information, contact Licensing@lanl.gov.


Visit Blogger Join Us on Facebook Follow Us on Twitter See our Flickr Photos Watch Our YouTube Videos Find Us on LinkedIn Find Us on iTunesFollow Us on Pinterest